Cargando…

Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report

INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelosi, Ettore, Skanjeti, Andrea, Cistaro, Angelina, Arena, Vincenzo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292733/
https://www.ncbi.nlm.nih.gov/pubmed/18387191
http://dx.doi.org/10.1186/1752-1947-2-99
_version_ 1782152521414868992
author Pelosi, Ettore
Skanjeti, Andrea
Cistaro, Angelina
Arena, Vincenzo
author_facet Pelosi, Ettore
Skanjeti, Andrea
Cistaro, Angelina
Arena, Vincenzo
author_sort Pelosi, Ettore
collection PubMed
description INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PRESENTATION: We present the case of a 74-year-old man with Castleman's disease. The disease was detected with a contrast-enhanced computed tomography (CT) scan and a fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT study; diagnosis was made with histopathology. After treatment with surgical excision followed by chemotherapy, the disease response was evaluated using both diagnostic techniques. However, only the PET study was able to identify the spread of the disease to the abdominal lymph nodes, which were both enlarged and normal size, and, after treatment, to evaluate the disease response. CONCLUSION: Based on the results of previous case reports and on those of the present study, it seems that Castleman's disease has a high glucose metabolic activity. Therefore, the use of PET can be considered appropriate in order to stage or restage the disease and to evaluate the response of the disease to treatment.
format Text
id pubmed-2292733
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22927332008-04-12 Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report Pelosi, Ettore Skanjeti, Andrea Cistaro, Angelina Arena, Vincenzo J Med Case Reports Case Report INTRODUCTION: Castleman's disease is a rare lymphatic polyclonal disorder that is characterised by unicentric or multicentric lymph node hyperplasia and non-specific symptoms and signs including fever, asthenia, weight loss, enlarged liver and abnormally high blood levels of antibodies. CASE PRESENTATION: We present the case of a 74-year-old man with Castleman's disease. The disease was detected with a contrast-enhanced computed tomography (CT) scan and a fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT study; diagnosis was made with histopathology. After treatment with surgical excision followed by chemotherapy, the disease response was evaluated using both diagnostic techniques. However, only the PET study was able to identify the spread of the disease to the abdominal lymph nodes, which were both enlarged and normal size, and, after treatment, to evaluate the disease response. CONCLUSION: Based on the results of previous case reports and on those of the present study, it seems that Castleman's disease has a high glucose metabolic activity. Therefore, the use of PET can be considered appropriate in order to stage or restage the disease and to evaluate the response of the disease to treatment. BioMed Central 2008-04-03 /pmc/articles/PMC2292733/ /pubmed/18387191 http://dx.doi.org/10.1186/1752-1947-2-99 Text en Copyright © 2008 Pelosi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Pelosi, Ettore
Skanjeti, Andrea
Cistaro, Angelina
Arena, Vincenzo
Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title_full Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title_fullStr Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title_full_unstemmed Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title_short Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman's disease: a case report
title_sort fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with castleman's disease: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292733/
https://www.ncbi.nlm.nih.gov/pubmed/18387191
http://dx.doi.org/10.1186/1752-1947-2-99
work_keys_str_mv AT pelosiettore fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport
AT skanjetiandrea fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport
AT cistaroangelina fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport
AT arenavincenzo fluorodeoxyglucosepositronemissiontomographycomputedtomographyinthestagingandevaluationoftreatmentresponseinapatientwithcastlemansdiseaseacasereport